Viridian Therapeutics to Present at Three Upcoming Investor Conferences
February 22 2021 - 7:00AM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage
biopharmaceutical company, today announced that Jonathan Violin,
Ph.D., President and Chief Executive Officer of Viridian, will
present a company overview at the following upcoming investor
conferences:
Event: |
SVB Leerink 10TH
Annual Global Healthcare Conference 2021
(Virtual) |
Date: |
Wednesday, February 24TH |
Presentation Time: |
1:00 p.m. EST |
|
|
Event: |
Cowen 41ST Annual
Health Care Conference 2021 (Virtual) |
Date: |
Wednesday, March 3RD |
Presentation Time: |
11:40 a.m. EST |
|
|
Event: |
Oppenheimer 31ST
Annual Healthcare Conference 2021 (Virtual) |
Date: |
Tuesday, March 16TH |
Presentation Time: |
11:20 a.m. EST |
Webcast information for these events will be accessible on the
Events page under the Investors section of the Viridian
Therapeutics website at www.viridiantherapeutics.com. A replay of
the presentations will be archived on the website and available for
approximately 90 days following each live event.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing new
treatments for patients suffering from serious diseases but
underserved by today’s therapies. Viridian’s most advanced program,
VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in
development for thyroid eye disease (TED). Viridian is
headquartered in Boulder, Colorado, with research and development
operations in Waltham, Massachusetts. Learn more about Viridian and
our programs at www.viridiantherapeutics.com. Follow us on Twitter
@ViridianThera and on LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements may be identified by the use of words such
as, but not limited to, "anticipate," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "might," "plan,"
"potential," "predict," "project," "should," "target," "will," or
"would" or other similar terms or expressions that concern
Viridian’s expectation, strategy, plans or intentions. Forward
looking statements include, without limitation, statements
regarding the Company’s future research and clinical development
plans and the potential commencement of the Company’s Phase 2
clinical trial and the timing for any of these events.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on our
current beliefs, expectations and assumptions regarding the future
of our business, future plans and strategies, our clinical results
and other future conditions. New risks and uncertainties may emerge
from time to time, and it is not possible to predict all risks and
uncertainties. No representations or warranties (expressed or
implied) are made about the accuracy of any such forward-looking
statements. We may not actually achieve the forecasts disclosed in
our forward-looking statements, and you should not place undue
reliance on our forward-looking statements. Such forward-looking
statements are subject to a number of material risks and
uncertainties including but not limited to those set forth under
the caption “Risk Factors” in Viridian’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission (SEC) on
November 12, 2020 and in other filings Viridian makes with the SEC
from time to time. Any forward-looking statement speaks only as of
the date on which it was made. Neither we, nor our affiliates,
advisors or representatives, undertake any obligation to publicly
update or revise any forward-looking statement, whether as result
of new information, future events or otherwise, except as required
by law. These forward-looking statements should not be relied upon
as representing our views as of any date subsequent to the date
hereof.
Viridian Contacts:
Investors:Dan FerryLifeSci
Advisors617-430-7576IR@viridiantherapeutics.com
Media:Darby PearsonVerge Scientific
Communications703-587-0831PR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Jul 2023 to Jul 2024